Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8262170 | 0.81 | CYP3A4 (0.45) | MAPTALDH1A1POLBLCKKIT | |
| SCHEMBL3568818 | 0.80 | DGAT1 (0.43) | MAPK14HTTF10 | |
| SCHEMBL13678790 | 0.78 | RPS6KA3 (0.37) | MAPTALDH1A1POLBMAPK14F10 | |
| SCHEMBL77918 | 0.76 | MAPT (0.48) | MAPTALDH1A1MAPK14ALOX15HTT | |
| SCHEMBL30104800 | 0.76 | F10 (0.43) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL632873 | 0.76 | F10 (0.43) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL6259090 | 0.76 | ALDH1A1 (0.39) | MAPTALDH1A1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL4999286 | 0.74 | F10 (0.42) | ALDH1A1F10 | |
| SCHEMBL3830592 | 0.73 | ALDH1A1 (0.47) | ALDH1A1PDE3BPDE3AF10 | |
| SCHEMBL1027648 | 0.73 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-2076511-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| EP-1951717-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR XA | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-06 | — | — | EP | claimed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | claimed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| WO-2007057317-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-24 | — | — | WO | claimed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-7601752-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
| US-20060106016-A1 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-05-18 | — | — | US | disclosed |
| WO-2006048152-A2 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571154-A1 | Beta-aminoacid-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106016-A1 | Dicarboxamide derivatives | F2, F12, TFPI | MAPT 3567/4885ALDH1A1 1180/4885CA12 242/4885 |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | F2, F12, TFPI | MAPT 3567/4885ALDH1A1 1180/4885CA12 242/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | MAPT 4843/4885ALDH1A1 2287/4885CA12 325/4885 |
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | MAPT 4282/4885ALDH1A1 2056/4885CA12 1447/4885 |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | MAPT 4876/4885ALDH1A1 2514/4885CA12 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.